New shot shows promise for tough eczema in Mid-Stage trial
NCT ID NCT07167758
First seen Sep 30, 2025 · Last updated May 01, 2026 · Updated 27 times
Summary
This study tests whether an experimental drug, TRIV-509, can help adults with moderate to severe atopic dermatitis (eczema). About 95 participants will receive either TRIV-509 or a placebo for 16 weeks, then switch to the other treatment. The goal is to see if the drug improves skin symptoms and to check for side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ATOPIC DERMATITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Triveni Bio Site #1
Camp Hill, Pennsylvania, 17011, United States
-
Triveni Bio Site #10
South Bend, Indiana, 46617, United States
-
Triveni Bio Site #11
Fountain Valley, California, 17271, United States
-
Triveni Bio Site #12
Niagara Falls, Ontario, L2H 1H5, Canada
-
Triveni Bio Site #13
Ajax, Ontario, L1S 7K8, Canada
-
Triveni Bio Site #15
North York, Ontario, M2N 3A6, Canada
-
Triveni Bio Site #16
Bellaire, Texas, 77401, United States
-
Triveni Bio Site #17
Newmarket, Ontario, L3Y 5G8, Canada
-
Triveni Bio Site #18
Kyiv, 01135, Ukraine
-
Triveni Bio Site #21
Prague, 11000, Czechia
-
Triveni Bio Site #22
Ostrava, 70200, Czechia
-
Triveni Bio Site #23
Prague, 15000, Czechia
-
Triveni Bio Site #24
Chorzów, Silesian Voivodeship, 41-500, Poland
-
Triveni Bio Site #25
Katowice, Silesian Voivodeship, 4-600, Poland
-
Triveni Bio Site #26
Poznan, Wielkopolska, 61-731, Poland
-
Triveni Bio Site #27
Katowice, Silesian Voivodeship, 40-611, Poland
-
Triveni Bio Site #28
Warsaw, Masovian Voivodeship, 00-872, Poland
-
Triveni Bio Site #29
Sosnowiec, 41-200, Poland
-
Triveni Bio Site #3
Miami, Florida, 33016, United States
-
Triveni Bio Site #30
Poznan, Wielkopolska, 60-309, Poland
-
Triveni Bio Site #31
Pardubice, 530 02, Czechia
-
Triveni Bio Site #33
Wroclaw, Lower Silesian Voivodeship, 51-604, Poland
-
Triveni Bio Site #34
Budapest, 1066, Hungary
-
Triveni Bio Site #37
Prague, 13000, Czechia
-
Triveni Bio Site #38
Pleven, 5800, Bulgaria
-
Triveni Bio Site #39
Sofia, 1172, Bulgaria
-
Triveni Bio Site #4
San Diego, California, 92123, United States
-
Triveni Bio Site #41
Budapest, 1033, Hungary
-
Triveni Bio Site #43
Debrecen, 4032, Hungary
-
Triveni Bio Site #5
Dallas, Texas, 75230, United States
-
Triveni Bio Site #6
Indianapolis, Indiana, 46250, United States
-
Triveni Bio Site #8
Spokane, Washington, 99202, United States
Conditions
Explore the condition pages connected to this study.